We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
- Authors
Nakashima, Kazuhisa; Harashima, Saki; Kaneko, Rena; Tanaka, Ryuhei; Abe, Masakazu; Wada, Makoto; Iino, Keiko; Akechi, Tatsuo; Iihara, Hirotoshi; Imamura, Chiyo K.; Okuyama, Ayako; Ozawa, Keiko; Kim, Yong-il; Satomi, Eriko; Takeda, Masayuki; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi
- Abstract
Background: A standardized multi-day antiemetic regimen for multi-day chemotherapy remains elusive. This systematic review evaluated the efficacy and safety of multi-day antiemetic regimens in patients undergoing multi-day intravenous chemotherapy. Methods: We conducted a comprehensive search of PubMed, Cochrane Library, and Ichushi-Web databases for relevant studies published from January 1990 to December 2020. We included studies comparing multi-day and single-day antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Results: No studies directly comparing multi-day versus single-day antiemetic regimens were found. Despite expanding control group criteria beyond "single-day antiemetic therapy" limited high-quality studies and variations in cancer types, chemotherapy regimens, and antiemetic treatments precluded meta-analysis. Among the included studies, some randomized controlled trials (RCTs) focused on complete response and vomiting rates. Two studies comparing two- and three-drug combinations reported higher complete response and no-vomiting rates with the three-drug regimen. Limited RCTs explored "nausea control" and "cost," and assessing "adverse events" proved challenging due to inconsistent reporting. Conclusion: The research on multi-day antiemetic therapy is limited, necessitating further investigation. Nonetheless, our findings suggest that three-drug combination therapy, including aprepitant, may offer superior antiemetic efficacy compared to two-drug regimens. Multi-day antiemetic therapy is strongly recommended during multi-day intravenous administration of cytotoxic anticancer drugs.
- Subjects
INTRAVENOUS therapy; RANDOMIZED controlled trials; ANTINEOPLASTIC agents; ANTIEMETICS; CHEMOTHERAPY complications
- Publication
International Journal of Clinical Oncology, 2025, Vol 30, Issue 1, p17
- ISSN
1341-9625
- Publication type
Academic Journal
- DOI
10.1007/s10147-024-02652-7